Search

Ou U Li

from San Ramon, CA
Age ~58
Get Report
Also known as:
Li Ou, Li Qu
Phone and address:
2038 Mornington Ln, San Ramon, CA 94582
Related to:
Siu Y Hung, 54Charlie Li, 59
Connected to:
Aici Li, 51Anbei L Li, 70Arden Y Li, 42Baiyong Li, 55Biao Li, 56Binglin Li, 43Candace H Li, 30Changhong Li, 56Chenglong Li, 59Chine E Li, 55

Ou Li Phones & Addresses

  • 2038 Mornington Ln, San Ramon, CA 94582
  • Tracy, CA
  • Las Vegas, NV
  • 5662 Portrush Pl, San Jose, CA 95138 (408) 223-2170
  • Roosevelt Corner, CA
  • Hanover, NH
  • Los Angeles, CA

Work

Company: Kixeye inc Aug 2012 Position: User interface artist

Education

School / High School: The Art Institute of California- San Francisco, CA 2003 Specialities: B.S in Media Arts & Animation

Resumes

Resumes

Ou Li Photo 1

Ou Li

View page
Ou Li Photo 2

Ou Li San Francisco, CA

View page
Work:
KIXEYE Inc

Aug 2012 to 2000
User Interface Artist
Tagged Inc
San Francisco, CA
Jan 2012 to Aug 2012
User Interface Visual Designer
Funtactix Inc
Los Angeles, CA
Dec 2010 to Dec 2011
User Interface Artist (Social Games)
Activision
Iowa City, IA
Jul 2006 to Dec 2010
Senior Artist (Console Games)
Pirate Games Ltd
San Francisco, CA
Aug 2004 to Jun 2006
Animation Coordinator/ Game Artist
Morning Sun Animation Co. and Wang Film Animation Production Co

Aug 1991 to Jan 2000
2D Layout Artist / Key-pose Animator / Clean
Education:
The Art Institute of California
San Francisco, CA
2003
B.S in Media Arts & Animation

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ou Li
President
MORELI INC
Business Services at Non-Commercial Site · Nonclassifiable Establishments
5662 Portrush Ct, San Jose, CA 95138
5662 Portrush Pl, San Jose, CA 95138
Ou Li
President
The New Century Real Estate Services Corp
3194 De Ln Cruz Blvd, Santa Clara, CA 95054

Publications

Us Patents

Treatment Of Cancer Using Inhibitors Of Tgf-Beta And Pd-1

View page
US Patent:
20200308266, Oct 1, 2020
Filed:
Jun 15, 2020
Appl. No.:
16/901596
Inventors:
- Emeryville CA, US
- Oakland CA, US
Ou Li - Dublin CA, US
International Classification:
C07K 16/22
C07K 16/28
Abstract:
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Treatment Of Cancer Using Inhibitors Of Tgf-Beta And Pd-1

View page
US Patent:
20190112366, Apr 18, 2019
Filed:
Dec 17, 2018
Appl. No.:
16/222725
Inventors:
- Oakland CA, US
Ou Li - Dublin CA, US
International Classification:
C07K 16/22
C07K 16/28
Abstract:
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Antibody Fragments Against The Insulin Receptor And Uses Thereof To Treat Hypoglycemia

View page
US Patent:
20180251562, Sep 6, 2018
Filed:
Feb 15, 2018
Appl. No.:
15/897852
Inventors:
- Emeryville CA, US
Toshihiko Takeuchi - Emeryville CA, US
Hassan Issafras - Emeryville CA, US
Kiranjit Ahluwalia - Emeryville CA, US
John Corbin - Emeryville CA, US
lra Goldfine - Emeryville CA, US
Kirk Johnson - Emeryville CA, US
Ou Li - Emeryville CA, US
Daniel Bedinger - Emeryville CA, US
International Classification:
C07K 16/28
A61K 45/06
A61K 39/395
A61K 39/00
Abstract:
The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibodies That Bind Interleukin-2 And Uses Thereof

View page
US Patent:
20180094053, Apr 5, 2018
Filed:
Sep 28, 2017
Appl. No.:
15/718152
Inventors:
- Berkeley CA, US
- Charleston SC, US
Hassan Issafras - Emeryville CA, US
Llewelyn Lao - San Francisco CA, US
Ou Li - Dublin CA, US
Daniel H. Bedinger - Pleasant Hill CA, US
Kristin Camfield Lind - Oakland CA, US
Agnes Choppin Holmes - Mountain View CA, US
Toshihiko Takeuchi - Oakland CA, US
Lauren Schwimmer - Alameda CA, US
Hoa Giang - Alameda CA, US
Amer M. Mirza - San Francisco CA, US
Kirk W. Johnson - Moraga CA, US
International Classification:
C07K 16/24
A61K 38/20
A61K 39/395
C07K 16/28
C07K 16/18
A61P 35/00
A61P 31/04
A61P 11/06
A61P 37/06
Abstract:
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibody Fragments Against The Insulin Receptor And Uses Thereof To Treat Hypoglycemia

View page
US Patent:
20170037135, Feb 9, 2017
Filed:
Aug 5, 2016
Appl. No.:
15/230340
Inventors:
- Berkeley CA, US
Toshihiko Takeuchi - Oakland CA, US
Hassan Issafras - Kensington CA, US
Kiranjit Ahluwalia - Fremont CA, US
John Corbin - Oakland CA, US
Ira Goldfine - Belvidere CA, US
Kirk Johnson - Moraga CA, US
Ou Li - Dublin CA, US
Daniel Bedinger - Pleasant Hill CA, US
International Classification:
C07K 16/28
A61K 45/06
A61K 39/395
Abstract:
The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Treatment Of Cancer Using Inhibitors Of Tgf-Beta And Pd-1

View page
US Patent:
20160289315, Oct 6, 2016
Filed:
Apr 3, 2016
Appl. No.:
15/089579
Inventors:
- Berkeley CA, US
- Oakland CA, US
Ou Li - San Francisco CA, US
International Classification:
C07K 16/22
C07K 16/28
Abstract:
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Control profile
Ou U Li from San Ramon, CA, age ~58 Get Report